Andrew SD - Search Results

1

Glucocorticoids differentially inhibit expression of the RET proto-oncogene.

Capes-Davis A, Andrew SD, Hyland VJ, Twigg S, Learoyd DL, Dwight T, Marsh DJ, Robinson BG. Capes-Davis A, et al. Among authors: andrew sd. Gene Expr. 1999;8(5-6):311-26. Gene Expr. 1999. PMID: 10947080 Free PMC article.

2

Transcriptional repression of the RET proto-oncogene by a mitogen activated protein kinase-dependent signalling pathway.

Andrew SD, Capes-Davis A, Delhanty PJ, Marsh DJ, Mulligan LM, Robinson BG. Andrew SD, et al. Gene. 2002 Sep 18;298(1):9-19. doi: 10.1016/s0378-1119(02)00919-8. Gene. 2002. PMID: 12406571

3

Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma.

Marsh DJ, Andrew SD, Eng C, Learoyd DL, Capes AG, Pojer R, Richardson AL, Houghton C, Mulligan LM, Ponder BA, Robinson BG. Marsh DJ, et al. Among authors: andrew sd. Cancer Res. 1996 Mar 15;56(6):1241-3. Cancer Res. 1996. PMID: 8640806

4

Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma.

Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL, Delbridge L, Eng C, Robinson BG. Marsh DJ, et al. Among authors: andrew sd. Clin Endocrinol (Oxf). 1996 Mar;44(3):249-57. doi: 10.1046/j.1365-2265.1996.681503.x. Clin Endocrinol (Oxf). 1996. PMID: 8729519

5

The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families.

Marsh DJ, McDowall D, Hyland VJ, Andrew SD, Schnitzler M, Gaskin EL, Nevell DF, Diamond T, Delbridge L, Clifton-Bligh P, Robinson BG. Marsh DJ, et al. Among authors: andrew sd. Clin Endocrinol (Oxf). 1996 Feb;44(2):213-20. doi: 10.1046/j.1365-2265.1996.505292.x. Clin Endocrinol (Oxf). 1996. PMID: 8849577

6

Deletion-insertion mutation encompassing RET codon 634 is associated with medullary thyroid carcinoma.

Marsh DJ, Andrew SD, Learoyd DL, Pojer R, Eng C, Robinson BG. Marsh DJ, et al. Among authors: andrew sd. Hum Mutat. 1998;Suppl 1:S3-4. doi: 10.1002/humu.1380110102. Hum Mutat. 1998. PMID: 9452023 No abstract available.

7

Sp1 and Sp3 transactivate the RET proto-oncogene promoter.

Andrew SD, Delhanty PJ, Mulligan LM, Robinson BG. Andrew SD, et al. Gene. 2000 Oct 3;256(1-2):283-91. doi: 10.1016/s0378-1119(00)00302-4. Gene. 2000. PMID: 11054558

8

A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families.

Marsh DJ, Robinson BG, Andrew S, Richardson AL, Pojer R, Schnitzler M, Mulligan LM, Hyland VJ. Marsh DJ, et al. Genomics. 1994 Sep 15;23(2):477-9. doi: 10.1006/geno.1994.1526. Genomics. 1994. PMID: 7835899

9

Regulation of c-Ret in the developing kidney is responsive to Pax2 gene dosage.

Clarke JC, Patel SR, Raymond RM Jr, Andrew S, Robinson BG, Dressler GR, Brophy PD. Clarke JC, et al. Hum Mol Genet. 2006 Dec 1;15(23):3420-8. doi: 10.1093/hmg/ddl418. Epub 2006 Oct 17. Hum Mol Genet. 2006. PMID: 17047028

10

Mutation analysis of glial cell line-derived neurotrophic factor, a ligand for an RET/coreceptor complex, in multiple endocrine neoplasia type 2 and sporadic neuroendocrine tumors.

Marsh DJ, Zheng Z, Arnold A, Andrew SD, Learoyd D, Frilling A, Komminoth P, Neumann HP, Ponder BA, Rollins BJ, Shapiro GI, Robinson BG, Mulligan LM, Eng C. Marsh DJ, et al. Among authors: andrew sd. J Clin Endocrinol Metab. 1997 Sep;82(9):3025-8. doi: 10.1210/jcem.82.9.4197. J Clin Endocrinol Metab. 1997. PMID: 9284737

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters